Sagimet Biosciences (SGMT) Net Cash Flow (2022 - 2026)
Sagimet Biosciences (SGMT) posted quarterly Net Cash Flow of $1.6 million for Q1 2026, up 114.43% year-over-year from $748497.5 in Q1 2025, and down 36.44% quarter-over-quarter from $2.5 million in Q4 2025.
Sagimet Biosciences (SGMT) Net Cash Flow (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Net Cash Flow history runs 5 years deep, the most recent figure standing at $1.6 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 114.43% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at -$28.1 million (up 74.93% YoY), while the FY2025 annual figure was -$40.8 million, down 5922.97% from the prior year.
- Net Cash Flow for Q1 2026 stood at $1.6 million, down from $2.5 million in the prior quarter.
- The five-year high for Net Cash Flow was $101.6 million in Q1 2024, with the low at -$80.8 million in Q2 2024.
- The 5-year median for Net Cash Flow is -$1.6 million (2022), against an average of $2.0 million.
- The sharpest annual moves came in 2023 and 2024: Net Cash Flow soared 205766.67% in 2023, then slumped 1409.85% in 2024.
- Sagimet Biosciences' Net Cash Flow stood at -$2.1 million in 2022, then tumbled by 1188.75% to -$26.7 million in 2023, then jumped by 95.6% to -$1.2 million in 2024, then jumped by 315.08% to $2.5 million in 2025, then slumped by 36.44% to $1.6 million in 2026.
- Business Quant data shows SGMT's Net Cash Flow at $1.6 million in Q1 2026, $2.5 million in Q4 2025, and -$9.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - | -35.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -35.12 Mn |
| Jun 30, 2026 | -35.12 Mn |
| Mar 31, 2026 | 1.61 Mn |
| Mar 31, 2026 | 1.61 Mn |
| Dec 31, 2025 | 2.53 Mn |
| Dec 31, 2025 | 2.53 Mn |
| Sep 30, 2025 | -9.83 Mn |
| Sep 30, 2025 | -9.83 Mn |
| Jun 30, 2025 | -22.39 Mn |
| Jun 30, 2025 | -22.39 Mn |
| Mar 31, 2025 | -11.12 Mn |
| Mar 31, 2025 | -11.12 Mn |
| Dec 31, 2024 | -1.17 Mn |
| Dec 31, 2024 | -1.17 Mn |
| Sep 30, 2024 | -18.95 Mn |
| Sep 30, 2024 | -18.95 Mn |
| Jun 30, 2024 | -80.82 Mn |
| Jun 30, 2024 | -80.82 Mn |
| Mar 31, 2024 | 101.64 Mn |
| Mar 31, 2024 | 101.64 Mn |